ST. LOUIS, MI (PRWEB) June 13, 2014
Multidistrict litigation (MDL) is continuing to progress in cases involving Lipitor, a cholesterol-lowering medication that has been linked to the development of type 2 diabetes, reports the national law firm of Baron and Budd. So far, more than 130 lawsuits have been transferred to the MDL. The lawsuits allege that the maker of Lipitor, Pfizer, either knew about the risk of diabetes or should have known about it yet failed to provide proper warnings. (In Re: Lipitor (atorvastatin calcium) marketing, sales practices and Products Liability Litigation, MDL No. 2502)
Lipitor is a statin, a drug designed to lower levels of LDL cholesterol in patients and, as a result, lower their risk of developing heart issues. However, the Archives of Internal Medicine published a study in 2012 that found women who used the drug were at risk of developing type 2 diabetes. According to the study, women between the ages of 50 and 70 who took the drug were nearly 50 percent more likely to develop the disease that women in the same age range who did not take the drug. (http://archinte.jamanetwork.com/article.aspx?articleid=1108676)
“We are pleased to see that Lipitor lawsuits are moving forward,” said Laura Baughman, shareholder at Baron and Budd. “Not only will we continue to monitor developments surrounding this case, we will also work to protect the rights of our clients who have been allegedly harmed after taking this drug.”
If you or someone close to you developed type 2 diabetes after taking Lipitor, the national law firm of Baron and Budd may be able to help. Call 866-472-9108 or visit our website at http://baronandbudd.com/areas-of-practice/pharmaceuticals/lipitor-lawsuit/ for more information.
ABOUT BARON & BUDD, P.C.
The attorneys at Baron and Budd have been Protecting What’s Right for consumers for more than 35 years. Over the years, our national law firm has built a successful track record representing people who have been harmed by corporate wrongdoing. The firm’s pharmaceutical lawyers recently represented over 7,000 patients harmed by using the drug Avandia. Previously, Baron & Budd played a prominent role in litigation related to the diet drug Fen-Phen. As a result, the case settled for an amount valued at more than $1.275 billion (In Re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, MDL No. 1203 (E.D. Pa.).